FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antagonist topics
Antagonist
Recurrence
Proliferative Disorder
Proliferative
Antibodies
Progesterone
Dicyclomine
Scopolamine
Extracellular
Pharmaceutically Acceptable Salt
Metalloprotein
Nucleic Acids
Polynucleotide
Nucleic Acid
Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antagonist patents



      
           
This page is updated frequently with new Antagonist-related patent applications. Subscribe to the Antagonist RSS feed to automatically get the update: related Antagonist RSS feeds. RSS updates for this page: Antagonist RSS RSS


Date/App# patent app List of recent Antagonist-related patents
12/18/14
20140371854
 Adjustable elastic antagonist muscle replacement mechanism patent thumbnailnew patent Adjustable elastic antagonist muscle replacement mechanism
The present invention is an anatomic system which uses the principle of applying higher elastic tonus than the rest tonus of the agonist muscles to provide the function of the antagonist muscles, and which is designed in a simplest way to provide the said purpose and which can be integrated to the body. The static mechanism of the invention is an elastic mechanism which applies a continuous stable tension in order to keep the joints open.
12/18/14
20140371467
 Glucagon receptor modulators patent thumbnailnew patent Glucagon receptor modulators
Or a pharmaceutically acceptable salt thereof wherein r1, r2, r3, a1, a2, a3, a4, l, b1, b2, b3 and b4 are as defined herein. The compounds of formula i have been found to act as glucagon antagonists or inverse agonists.
12/18/14
20140371284
 Imidazolidinedione compounds and their uses patent thumbnailnew patent Imidazolidinedione compounds and their uses
Provided are imidazolidinedione compounds of formula (i), processes for preparation, uses and pharmaceutically compositions thereof. Said imidazolidinedione compounds posses androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne..
12/18/14
20140371276
 Trpm8 antagonists patent thumbnailnew patent Trpm8 antagonists
The invention relates to compounds acting as selective antagonists of transient receptor potential cation channel subfamily m member 8 (trpm8), and having formula (i). Said compounds are useful in the treatment of diseases associated with activity of trpm8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders..
12/18/14
20140371274
 Bradykinin receptor antagonists and pharmaceutical compositions containing them patent thumbnailnew patent Bradykinin receptor antagonists and pharmaceutical compositions containing them
The present invention relates to novel compounds, their use in the prevention or treatment of symptoms and disorders associated with the bradykinin b1 pathway and pharmaceutical compositions containing them.. .
12/18/14
20140371265
 Compositions and methods for treatment patent thumbnailnew patent Compositions and methods for treatment
The present invention provides compounds and methods for the treatment of lfa-1 mediated diseases. In particular, lfa-1 antagonists are described herein and these antagonists are used in the treatment of lfa-1 mediated diseases.
12/18/14
20140371264
 Muscarinic acetylcholine receptor antagonists patent thumbnailnew patent Muscarinic acetylcholine receptor antagonists
Muscarinic acetylcholine receptor antagonists and methods of using them are provided.. .
12/18/14
20140371255
 Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation patent thumbnailnew patent Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation
Selective, non-peptide antagonists of the mu opioid receptor (mor) and methods of their use are provided. The antagonists may be used, for example, to identify mor agonists in competitive binding assays, and to treat conditions related to addiction in which mor is involved, e.g.
12/18/14
20140371218
 Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders patent thumbnailnew patent Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
And their use as therapeutic compounds.. .
12/18/14
20140371207
 Chemokine receptor antagonists and methods of use thereof patent thumbnailnew patent Chemokine receptor antagonists and methods of use thereof
Or physiologically acceptable salt thereof.. .
12/18/14
20140371181
new patent Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
Prodrugs of c-17-heterocyclic-steroidal drugs providing improved oral bioavailability and phamacokinetics are described. The drugs are inhibitors of human cyp 17 enzyme, as well as potent antagonists of both wild type and mutant androgen receptors (ar), and are useful for the treatment of urogenital and/or androgen-related cancers, diseases and/or conditions, such as human prostate cancer, breast cancer, and prostate hyperplasia.
12/18/14
20140370015
new patent Use of il-20 antagonists for alleviating spinal cord injury
Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an il-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by il-20. Such antibodies include anti-il-20 antibodies and anti-il-20r antibodies that specifically block the il-20 signaling pathway..
12/18/14
20140370014
new patent Use of il-20 antagonists for alleviating obesity
Alleviating obesity in a subject (e.g., a human subject) having, being suspected of having, or at risk for obesity using an il-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by il-20. Such antibodies include anti-il-20 antibodies and anti-il-20r antibodies that specifically block the il-20 signaling pathway..
12/18/14
20140369973
new patent Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
The present invention relates to methods, kits and compositions for expansion of hematopoietic stem/progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a notch agonist and an aryl hydrocarbon receptor antagonist.
12/11/14
20140364600
Imidazolyl progesterone antagonists
Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.. .
12/11/14
20140364473
Oral suspension comprising telmisartan
A pharmaceutical solution with a ph value of 10 or higher contains an angiotensin ii receptor antagonist, where one or more sugar alcohols are present up to a total concentration of 40 wt. % to 70 wt.
12/11/14
20140364445
Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
The present invention relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“trpa1”) antagonist and an anticholinergic agent. Particularly, the present invention provides a pharmaceutical composition comprising a trpa1 antagonist having ic50 for inhibiting human trpa1 receptor activity of less than 1 micromolar and an anticholinergic agent; a process for preparing such composition; and its use in treating a respiratory disorder in a subject..
12/11/14
20140364433
Substituted prolines / piperidines as orexin receptor antagonists
The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
12/11/14
20140364432
Substituted prolines / piperidines as orexin receptor antagonists
The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
12/11/14
20140364424
Novel sulfonaminoquinoline hepcidin antagonists
The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.. .
12/11/14
20140364420
Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
Or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of chemokine receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders..
12/11/14
20140364418
Compositions comprising an aromatic alcohol and a trpv-1 antagonist, and uses thereof
A topical composition providing reduced irritation that contains aromatic alcohols such as phenoxyethanol and a trpv-1 antagonist is described. The composition is substantially free of parabens.
12/11/14
20140364415
Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors
And their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as trk antagonists.. .
12/11/14
20140363445
Method of treating cancer comprising a vegf-b antagonist
The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue.
12/11/14
20140363432
Vascular endothelial cell growth factor antagonists and uses thereof
The present invention provides vascular endothelial cell growth factor (vegf) antagonists and methods of using vegf antagonists. Vegf antagonists contemplated by the invention include vegf antibodies and vegf receptor fusion proteins.
12/04/14
20140357858
P2x4 receptor antagonist
The present invention relates to a diazepine derivative represented by the following general formula (i) (in the formula, r1 and r2 represent hydrogen atom and the like, or r1 and r2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, r3 and r4 represent hydrogen atom and the like, r5 represents hydrogen atom and the like, r6 and r7 represent hydrogen atom and the like, x represents c, ch or n, y represents n, nh or c(═o), provided that when x is n, y is not n or nh, and when x is c or ch, y is not c(═o), z represents oxygen atom or sulfur atom, a represents benzene ring and the like, b represents nhc(═o) and the like, d represents an atomic bond and the like, e represents an atomic bond and the like, g represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a p2x4 receptor antagonist.. .
12/04/14
20140357724
Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
Methods of treating orthostatic hypotension are disclosed. The methods include administering to a subject in need thereof an effective amount of a beta 2 (β2) adrenoceptor antagonist, and in particular, the specific β2 adrenoceptor antagonist, 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol..
12/04/14
20140357682
Androgen receptor ligands
Non ligand binding pocket antagonists for the human androgen receptor. The androgen receptor (ar) is a member of the nuclear receptor (nr) family and its role is to modulate the biological effects of the endogenous androgens, testosterone (tes) and dihydrotestosterone (dht).
12/04/14
20140357658
Opioid agonist/opioid antagonist/acetaminophen combinations
The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome)..
12/04/14
20140357655
Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists
Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (gnrh) receptor antagonists..
12/04/14
20140357653
Chemical compounds
The invention relates to a novel compound of formula (i) or a stereoisomer, or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein: r is phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from s, n and o, such rings may be optionally substituted with n groups q; q is selected from a group consisting of: c1-c4 alkyl, halogen, halo c1-c4 alkyl, c1-c4 alkoxy, cn, so2ch3 or a group —o[(cr1r2]pq1; or q may be a group q2; q1 is phenyl, which may be optionally substituted with n substituents selected from a group consisting of: c1-c4 alkyl, halogen, halo c1-c4 alkyl, c1-c4 alkoxy, cn, or a group q2; or corresponds to 2,2-difluoro-benzo[d][1,3]dioxol-4-yl; q2 is a 5- or 6-membered heteroaryl containing at least one nitrogen atom, which may optionally substituted with n substituents selected from a group consisting of: cl c1-c4 alkyl, halogen, halo c1-c4 alkyl, c1-c4 alkoxy, cn; p is a 6-membered heteroaryl or a 8-1 1 membered bicyclic heteroaryl group, which may be substituted with n substituents selected from a group consisting of: c1-c4 alkyl, halogen, halo c1-c4 alkyl, c1-c4 alkoxy, cn; r1 is hydrogen or c1-c3 alkyl; r2 is hydrogen or c1-c3 alkyl; n is 1, 2 or 3; p is 0, 1 or 2; and with the proviso that when r corresponds to phenyl, p is substituted by at least one cf3; processes for the preparation of those compounds, pharmaceutical compositions containing one or more compounds of formula (i) and their use as dual antagonists of the orexin 1 and orexin 2 receptors.. .
12/04/14
20140357645
Advanced formulations and therapies for treating hard-to-heal wounds
A method for healing a hard-to-heal wound including the steps of: topically administering a wound healing composition to a wounded area, wherein the wound healing composition includes, at least one of: (a) a medicament characterized as a calcium channel blocker or pharmaceutically acceptable salts or solvates thereof; (b) a medicament characterized as an alpha-adrenergic antagonist or pharmaceutically acceptable salts or solvates thereof; (c) a medicament characterized as a direct vasodilator or pharmaceutically acceptable salts or solvates thereof; and (d) a medicament characterized as a phosphodiesterase type five inhibitor or pharmaceutically acceptable salts or solvates thereof; and (e) a hemorrheologic agent or pharmaceutically acceptable salts or solvates thereof; (f) a primary dermal penetrating agent or pharmaceutically acceptable salts or solvates thereof: and (g) a topical stimulating agent or pharmaceutically acceptable salts or solvates thereof.. .
12/04/14
20140357629
Diaminopyrimidines as p2x3 and p2x2/3 antagonists
Wherein d, x, y, r1, r2, r3, r4, r5, r6, r7 and r8 are as defined herein.. .
12/04/14
20140356372
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (sit) regimen.
12/04/14
20140356359
Human growth hormone receptor antagonist antibodies and methods of use thereof
The present invention provides antagonizing antibodies that bind to growth hormone receptor (ghr). The invention further relates to therapeutic methods for use of these antibodies to reduce igf-1 levels and/or for the treatment and/or prevention of diseases associated with excessive igf-1, including treatment of acromegaly, gigantism, cancer, diabetic nephropathy, arthritis, and lung inflammation..
12/04/14
20140356342
Human beta-adrenergic receptor kinase polypeptide and methods
Various embodiments of the invention provide human kinases and phosphatases (kpp) polypeptides and polynucleotides which identify and encode kpp. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists.
11/27/14
20140350226
Rspondins as modulators of angiogenesis and vasculogenesis
The present invention relates to the use of rspondins, particularly rspondin2 (rspo2) or rspondin3 (rspo3) or rspondin nucleic acids, or regulators or effectors or modulators of rspondin, e.g. Rspo2 and/or rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively.
11/27/14
20140350056
Trpv1 antagonists including dihydroxy substituent and uses thereof
And pharmaceutically acceptable derivatives thereof wherein ar1, ar2, l1, l2, x, r3, r22, and m are as defined herein, compositions comprising an effective amount of a compound of formula (i), and methods for treating or preventing a condition such as pain, ui, an ulcer, ibd and ibs, comprising administering to an animal in need thereof an effective amount of a compound of formula (i).. .
11/27/14
20140350046
Pyrazolopyridinone derivatives as lpa receptor antagonists
The present invention relates to novel pyrazolopyridinone derivatives according to formula (i) and a process of manufacturing thereof. These pyrazolopyridinone derivatives can be used as lpa receptor antagonists for the treatment of various herein disclosed diseases..
11/27/14
20140350043
Fsh receptor antagonists
The invention relates to fsh receptor antagonist according to general formula (i) or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders..
11/27/14
20140350035
Combinations of medicaments, containing pde4-inhibitors and ep4-receptor- antagonists
At least one ep4 receptor antagonist (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.. .
11/27/14
20140350005
D2 antagonists, methods of synthesis and methods of use
And pharmaceutically acceptable salts thereof, or isomers thereof, wherein r1, r2 and r3 are as defined herein. The invention further comprises methods for making the compounds of the invention and methods for the treatment of conditions mediated by the dopamine d2 or d3 receptor from the compounds of the invention..
11/27/14
20140349968
Compositions and methods for treating cancer
The instant invention provides a method of treating a cancer selected from the group consisting of non-small cell lung cancer and breast cancer with an mtor inhibitor and an αv62 3 integrin antagonist, wherein the mtor inhibitor is ridaforolimus, everolimus, temsirolimus or a combination thereof.. .
11/27/14
20140348849
Compounds and method for modulating inflammatory reactions
The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the present invention are cell migration, secretion of toxic products and proteolysis at a site of inflammation.
11/27/14
20140348847
Antibodies against human il-12
The present invention relates to novel p75 heterodimer specific anti-human il-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human il-12 bioactivity than known heterodimer specific il-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human il-12 p75 heterodimer, but do not bind to the p40 subunit alone.
11/20/14
20140343256
Tlr2 antagonistic antibody and use thereof
The present invention is directed to a cross-reactive antibody, which specifically inhibits or blocks the mammalian toll-like receptor 2 (tlr2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of said antibody.
11/20/14
20140343250
Recombinant bacteria recognizing protein and uses thereof
The present invention relates to a recombinant protein comprising seq id no: 1 and a bacteria recognizing lectin. The present invention also relates to uses of the recombinant protein comprising detecting pathogens, removing endotoxins, determining the presence of an endotoxin or endotoxin-like material, and determining the presence of pathogen-associated molecular pattern (pamp) comprising rhamnose-rhamnose (rha-rha), rhamnose-n-acetyl-mannosamine (rha-mannac), n-acetyl-mannosamine-rhamnose (mannac-rha), rhamnose-galatose (rha-gal), or galatose-rhamnose (gal-rha) in a sample, and use as a medicament, a disinfectant, a decontaminant, a surfactant or a diagnostic means.
11/20/14
20140343151
Leukotriene b4 antagonist compound
The present invention provides a compound of formula (i): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of formula (i) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
11/20/14
20140343041
Topical ophthalmic formulations for the treatment and prevention of migraine headache
The present invention provides topical ophthalmic formulations comprising a combination of one or more antihistamine agents and optionally one or more vasculature modifying agents such as a β adrenergic receptor antagonist. Also provided are methods of using the formulations of the invention for treating and/or preventing symptoms associated with migraine headache, and for reducing the frequency, severity and duration of migraine attacks..
11/20/14
20140343022
Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
The subject matter of the instant invention is pertinent to the field of cancer treatment. In particular, the instant invention is relevant to the treatment and or prevention of breast cancer in a patient.
11/20/14
20140341948
Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
In particular, the invention relates to attenuated influenza viruses having modifications to the ns1 gene that diminish or eliminate the ability of the ns1 gene product to antagonize the cellular ifn response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations..
11/20/14
20140341920
Vista modulators for diagnosis and treatment of cancer
The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of vista, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as pd-1.
11/20/14
20140341902
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
The present invention describes combination treatment comprising a pd-1 axis binding antagonist and a mek inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.. .
11/20/14
20140341896
Humanized anti-human nkg2a monoclonal antibody
The present invention relates to agents that are non-competitive antagonists of the cd94/nkg2a receptor such as certain anti-nkg2a antibodies, in particular humanized versions of murine anti-nkg2a antibody z199, as well as methods of producing and using such agents and antibodies.. .
11/20/14
20140341849
Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound..
11/20/14
20140341810
Antagonists for abdominal vasopressin v2 receptor and uses thereof
Provided herein are antagonists or binding agents of an abnormal vasopressin receptor v2 (e.g., abnv2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor v2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro.
11/20/14
20140341802
Provasopressin antagonists and uses thereof
Provided herein are pro-vp antagonists, such as antibodies and antigen-binding portions thereof specific for pro-vp, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples.
11/13/14
20140336383
Prolyl hydroxylase inhibitors
Which are antagonists of hif prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.. .
11/13/14
20140336381
Fast-dissociating dopamine 2 receptor antagonists
The present invention relates to 4-aryl-6-piperazin-1-yl-3-substituted-pyridazines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects..
11/13/14
20140336374
Process and intermediates for the production of ccr2 antagonists
The present invention relates to a process for the production of novel antagonists for ccr2 (cc chemokine receptor 2) and intermediates thereof.. .
11/13/14
20140336365
Cdr regions of monoclonal antibody that antagonize sphinogosine 1-phosphate and related methods
Materials and method for treating cancer and screening for anti-neoplastic agents are provided. These materials and methods can include sphingosine 1-phosphate antagonists that bind to sphingosine-1 phosphate receptor subtype 3.
11/13/14
20140336266
Method for administering an nmda receptor antagonist to a subject
Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided.
11/13/14
20140336258
Anti-virulence compositions and methods
A method of reducing the virulence of a bacterium that expresses accessory gene regulator a (agra) includes administering to the bacterium an amount of agra antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.. .
11/13/14
20140336224
Mineralocorticoid receptor antagonists
Compounds of the formula (i) as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases are disclosed. Processes for preparing compounds of the formula (i), use of the compounds for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and pharmaceutical compositions which comprise compounds of the formula (i) are disclosed..
11/13/14
20140336212
Combination analgesic employing opioid agonist and neutral antagonist
In some embodiments, the invention provides a non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject (such as a human) and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects of the opioid agonist, and insufficient to block substantial central effects of the opioid agonist in the subject. The formulation may be formulated for oral administration to the subject.
11/13/14
20140336183
Compositions and method for treatment of ischemic neuronal reperfusion injury
A method and composition for the treatment of ischemic neuronal reperfusion injury are provided. The composition may include at least a benzodiazepine class material.
11/13/14
20140336172
Novel 2h-indazoles as ep2 receptor antagonists
The present invention relates to novel 2h-indazoles of the general formula (i), methods for the preparation thereof and the use thereof for the production of pharmaceutical agents for the treatment of diseases and indications which are linked with the ep2-receptor.. .
11/13/14
20140336158
Nk1 antagonists
Wherein ar1 and ar2 are optionally substituted phenyl or heteroaryl, x1 is an ether, thio or imino linkage, r4 and r5 are not both h or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions.
11/13/14
20140336142
Method for treatment of macular degeneration by modulating p2y12 or p2x7 receptors
Provided is a method of treating or preventing age-related macular degeneration (amd) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal ph (phl), or acidifying an abnormally elevated phl, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in the retinal pigment epithelium (rpe) cells of the eye of the patient. Further, this method is achieved by modulating the action of the p2x7 and/or p2y12 receptors of the rpe cells, specifically decreasing the acidity (phl) of the rpe lysosomes by administering selected receptor antagonists affecting the action of the p2x7 and/or p2y12 receptors of the rpe.
11/13/14
20140336117
Modified receptor fusion proteins
We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.. .


Popular terms: [SEARCH]

Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



0.5986

3351

0 - 1 - 72